A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of ...

French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...

MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

When Anne Maldzinski underwent a blood stem-cell transplant to cure her cancer, the procedure triggered a life-threatening ...

MaaT Pharma reports positive Phase III results for MaaT013, its microbiome-based therapy for gastrointestinal GvHD, achieving ...

MaaT Pharma to host a KOL webinar on December 17 th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) - Register here. Sustained High Response Rates at ...

French-based MaaT Pharma is eyeing up a Phase II study of its immune system modulator after its Phase Ib trial in patients with amyotrophic lateral sclerosis (ALS) met all of its primary endpoints.

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

“万一我告诉你，未来的药物可能不仅是从实验室里的培养皿中提取，而是来自我们的肠道菌群，你会觉得这是科学幻想吗 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...